 CA-125 Antigen
"CA-125 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces.
| Descriptor ID |
D018394
|
| MeSH Number(s) |
D12.776.395.560.631.050 D23.050.285.050.225 D23.050.550.325.225 D23.101.140.075.225
|
| Concept/Terms |
CA-125 Antigen- CA-125 Antigen
- Antigen, CA-125
- Antigen CA-125
- Antigen CA 125
- Mucin-16
- Mucin 16
- CA 125 Antigen
- Antigen, CA 125
|
Below are MeSH descriptors whose meaning is more general than "CA-125 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Mucoproteins [D12.776.395.560]
- Mucins [D12.776.395.560.631]
- CA-125 Antigen [D12.776.395.560.631.050]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Neoplasm [D23.050.285]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
- CA-125 Antigen [D23.050.285.050.225]
- Epitopes [D23.050.550]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
- CA-125 Antigen [D23.050.550.325.225]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
- CA-125 Antigen [D23.101.140.075.225]
Below are MeSH descriptors whose meaning is more specific than "CA-125 Antigen".
This graph shows the total number of publications written about "CA-125 Antigen" by people in this website by year, and whether "CA-125 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "CA-125 Antigen" by people in Profiles.
-
Wang Q, Ma X, Wu H, Zhao C, Chen J, Li R, Yan S, Li Y, Zhang Q, Song K, Yuan C, Kong B. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer. Oncoimmunology. 2022; 11(1):2096362.
-
Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B, Rimel BJ. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One. 2021; 16(6):e0252665.
-
Mortaji P, Lebduska E. The Dangers of Using Tumor Markers to Evaluate Nonspecific Symptoms: A Teachable Moment. JAMA Intern Med. 2020 07 01; 180(7):1004.
-
Nasioudis D, Wilson E, Mastroyannis SA, Latif NA. Prognostic significance of elevated pre-treatment serum CA-125 levels in patients with stage I ovarian sex cord-stromal tumors. Eur J Obstet Gynecol Reprod Biol. 2019 Jul; 238:86-89.
-
Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep. 2018 10 03; 8(1):14725.
-
Schwartz ZP, Frey MK, Philips S, Curtin JP. Endometrial cancer surveillance adherence reduces utilization and subsequent costs. Gynecol Oncol. 2017 09; 146(3):514-518.
-
Buas MF, Gu H, Djukovic D, Zhu J, Drescher CW, Urban N, Raftery D, Li CI. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol. 2016 Jan; 140(1):138-44.
-
Elias AD, Sams S. Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR. Oncology (Williston Park). 2013 Jun; 27(6):526-7, 566.
-
Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, Richard SD, Krivak TC. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer. 2011 Aug; 21(6):1013-7.
-
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 08; 305(22):2295-303.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|